Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00057980 · ClinicalTrials.gov registry record · Phase 1
Epirubicin and Celecoxib in Treating Patients With Hepatocellular Carcinoma
A Phase 1 study, sponsored by Northwestern University.
- Completed
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT00057980 is a Phase 1 study that has completed, run by Northwestern University. The registered enrollment target is 8 participants.
The verdict
NCT00057980, a Phase 1 study, has completed, sponsored by Northwestern University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
RATIONALE: Celecoxib may stop the growth of tumor cells by stopping blood flow to the tumor. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining celecoxib with epirubicin may kill more tumor cells. PURPOSE: This phase I/II trial is studying the side effects and best dose of epirubicin when given together with celecoxib and to see how well it works in treating patients with hepatocellular carcinoma (liver cancer).
Interventions
- DRUG epirubicin hydrochloride
- DRUG celecoxib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2002-10 |
| Est. Completion | 2007-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00057980
The ClinicalTrials.gov registry entry for NCT00057980 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Northwestern University, which has 1,209 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which epirubicin hydrochloride is the first listed.
NCT00057980 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00057980 about?
NCT00057980 is a clinical study titled "Epirubicin and Celecoxib in Treating Patients With Hepatocellular Carcinoma". RATIONALE: Celecoxib may stop the growth of tumor cells by stopping blood flow to the tumor. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining celecoxib with epirubicin may kill more tumor cells. PURPOSE: This phase I/II trial is ...
What is the current status of trial NCT00057980?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2002-10. Estimated completion is 2007-02.
What interventions are being tested in trial NCT00057980?
The interventions under investigation include: epirubicin hydrochloride (DRUG), celecoxib (DRUG).
Who is sponsoring clinical trial NCT00057980?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.